AstraCe – active action mucolytic for coughing

A cough is a defense reaction of the body that clears the airways from everything that interferes with normal breathing: mucus, dust, food particles. It is also the main symptom of chronic obstructive pulmonary disease (COPD), a condition of persistent airway restriction that is not completely reversible.

Today, on World COPD Day, Astrapharm strives to remind once again that this disease can be prevented and treated!

  •  quit smoking, a leading risk factor for COPD;
  •  follow a healthy lifestyle: be physically active and eat a balanced diet;
  •  avoid contact with polluted air;
  •  get vaccinated against influenza and pneumococcal infections in a timely manner.

If the disease has already occurred, bronchodilator and mucolytic therapy for COPD will help control its course and live a full life. For this purpose, Astrapharm launches a mucolytic, expectorant agent, AstraCe, on the Ukrainian pharmaceutical market.

The active ingredient of the drug is acetylcysteine, a derivative of the amino acid cysteine, which exhibits:

  •  powerful mucolytic effect – breaks the disulfide bonds of acidic mucopolysaccharides of phlegm, which makes it less viscous and promotes excretion when coughing;
  • local anti-inflammatory action – inhibits the synthesis of inflammatory mediators;
  • anti-infectious effect – enhances the therapeutic effect of antibiotics and destroys massive accumulations of bacteria in the lungs.

With COPD, a course of treatment with AstraTs is possible for up to six months.

AstraCe is available in the form of a 3 g sachet containing 200 mg of acetylcysteine.

The drug is dispensed without a prescription.

Astrapharm is the art of helping people!